- |||||||||| TRPH-222 / Triphase Accelerator Corporation, BMS
Highlighting the Phase I Pharmacokinetics & Safety Study of TRPH-222 in Patients with Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma () - Feb 9, 2022 - Abstract #ADCLondon2022ADC_London_119;
Collectively, these characteristics of TRPH-222 are favorable for further development in the indolent lymphoma setting either as monotherapy or in combination with other anti-tumor agents in B-cell lymphoma patients. Summarise the SMARTag technology and Phase I study design Review of the safety and efficacy of TRPH-222 in R/R NHL Presenting our thoughts on future directions for ADCs using novel payload linkers and moving beyond cytotoxic payloads
- |||||||||| TRPH-222 / Triphase Accelerator Corporation, BMS
[VIRTUAL] Phase I Pharmacokinetic (PK) & Safety Study of TRPH- 222 in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma () - Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_105;
Summarise the SMARTag technology and Phase I study design Review of the safety and efficacy of TRPH-222 in R/R NHL Presenting our thoughts on future directions for ADCs using novel payload linkers and moving beyond cytotoxic payloads Summarize the SMARTag technology and Phase 1 study design Review of the safety and efficacy of TRPH-222 in R/R NHL Presenting our thoughts on moving ADCs beyond the delivery of cytotoxic payloads
- |||||||||| TRPH-222 / Triphase Accelerator Corporation, BMS
[VIRTUAL] Catalent’s SMARTag® Technology: Differentiated Solutions for Optimal ADCs () - Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_101;
We are using new linkers to achieve proprietary high DAR ADCs featuring topoisomerase I inhibitor payloads. We have demonstrated conjugate stability—even with cleavable linkers—to deliver efficacy with improved tolerability and a wider therapeutic window.
- |||||||||| TRPH-222 / Triphase Accelerator Corporation, BMS
[VIRTUAL] TRPH-222: A Next-Generation ADC Targeting CD22 () - Aug 31, 2020 - Abstract #PEGS2020PEGS_191;
P1
TRPH-222 is a CD22-directed ADC, constructed via a novel, site-specific (SMARTag™) conjugation approach, resulting in highly controlled and reproducible drug loading. TRPH-222 is being studied in relapsed and/or refractory B cell lymphoma patients in a phase 1 clinical trial (NCT03682796); currently, the trial is enrolling patients in the dose-escalation phase, with promising tolerability, PK, and PD, as well as early signs of clinical efficacy in this single agent study.
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, TRPH-222 / Triphase Accelerator Corporation, BMS
[VIRTUAL] SMARTag® technology for the preparation of safe and efficacious site-specifically modified antibody-drug conjugates (On Demand Poster) - Aug 20, 2020 - Abstract #ACSFall2020ACS-Fall_5541;
Similarly, a SMARTag® dual-release cleavable linker offers improved plasma stability and better tolerability relative to standard cleavable linker motifs as highlighted by data from monomethylauristatin E (MMAE) conjugates. With impressive manufacturability, simplified analytics, and improved tolerability relative to other approaches, SMARTag® technology offers a clinically-validated way to make better ADCs.
- |||||||||| TRPH-222 / Triphase Accelerator Corporation, BMS
Enrollment open: Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma (clinicaltrials.gov) - Oct 19, 2018
P1, N=120, Recruiting,
With impressive manufacturability, simplified analytics, and improved tolerability relative to other approaches, SMARTag® technology offers a clinically-validated way to make better ADCs. Not yet recruiting --> Recruiting
|
